Ahmedabad-based drug maker Eris Lifesciences Ltd. has posted a 42 per cent rise in its consolidated net profit for the third quarter of financial year 2020-21 at Rs 90.1 crore. Last year the company registered a consolidated Q3 net profit of Rs 63.4 crore. The company's consolidated total income grew by 14 per cent to Rs 313.4 crore in the said quarter, as compared to Rs 274.8 crore in Q3 the previous fiscal. Overall, the company saw decent growth in its product segments, led by cardio metabolic and vitamin-mineral-nutrients (VMN). Excluding Covid molecules, the company saw a year-on-year (YoY) growth of 15.6 per cent as against a five per cent growth by the Indian Pharmaceutical Market (IPM) in Q3 of FY'21.